peptide T

peptide T

A short polypeptide derived from the HIV envelope protein gp120, which blocks binding and infection by HIV strains that infect cells via the CCR5 receptor. Peptide T was studied as a possible AIDS therapy, but failed in clinical trials.

peptide T,

n a biological substance administered intranasally, it may block the spread of HIV infection and combat related neurologic dysfunction.
References in periodicals archive ?
The protein, dubbed Peptide T, was isolated from the HIV envelope protein and is being tested on Swedish and U.
At a seminar last week, the NIMH investigators described evidence suggesting that Peptide T may protect brain and immune cells by mimicking a naturally occurring peptide -- vasoactive intestinal peptide (VIP).
Brenneman, VIP and Peptide T similarly protected mouse neurons in laboratory cultures from dying after exposure to low concentrations of the HIV envelope protein.
Peptide T may act at only one of those subtypes, she notes.
1, 1996--MacroChem Corporation (NASDAQ:MCHM) and Advanced Peptides and Biotechnology Sciences (ADVANCED PEPTIDES), Stony Brook, New York, have announced a joint agreement to conduct a feasibility study on the delivery of Peptide T to treat psoriasis with SEPA(R), MacroChem's patented transdermal drug delivery technology.
A 9-year study by the Psoriasis Research institute of Palo Alto, CA and Karolinska Institute, Sweden (sponsored by Advanced Peptides) has reported statistically significant efficacy in treating psoriasis with Peptide T in both HIV-positive and HIV-negative subjects, without adverse side effects.
We are optimistic that MacroChem's SEPA(R) technology will allow us to deliver Peptide T to affected areas in a topically applied formula instead of the needle injection method.
Advanced Peptides holds a co-exclusive license for Peptide T from the office of Technology Transfer, National Institutes of Health for HIV-1 indications, and expects approval for the expansion of the license to other applications.
reported today that Peptide Technology Limited intends to terminate all further activities and investment in the development of Peptide T for HIV/AIDS and will focus its product development efforts on GMDP, an orally active proprietary drug for the treatment of skin disorders such as psoriasis.
This decision by Peptech to terminate further development of Peptide T for HIV/AIDS follows the recent disclosure of preliminary results of primary efficacy data by the National Institute of Mental Health (NIMH) that there is no evidence that Peptide T has an effect on neuropsychological performance in HIV seropositive individuals who have cognitive impairment.
Drug Royalty has royalty interests with Peptide Technology Limited in Peptide T for HIV/AIDS and GMDP.
Peptide Technology recently completed preliminary analysis of its German Phase II trial on Peptide T in AIDS patients, which was aimed at examining general health related quality-of-life parameters and a range of neuropsychological functions as well as pain.